Physician profile
Bruce S Stein
NPI 1982631545
$34,973.11
in general payments reported to CMS, 2019-2025
43 companies · $3,179 in 2025
The $3,179 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,227 · 2020: $3,972 · 2021: $5,628 · 2022: $8,719 · 2023: $3,748 · 2024: $5,500 · 2025: $3,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,620 · Consulting Fee: $2,250 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350 · Education: $161 · Travel and Lodging: $47.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,619.60 |
| Consulting Fee | $2,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
| Education | $160.59 |
| Travel and Lodging | $47.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $6,771.35 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $5,745.44 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $4,702.41 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,830.45 | 2019-2025 | Evenity, Enbrel, Otezla |
| Pfizer INC. | $2,259.12 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,768.98 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $1,663.53 | 2019-2025 | Benlysta |
| Ucb, INC. | $1,601.99 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,306.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $889.03 | 2021-2025 | Saphnelo |
| Fidia Pharma USA INC. | $766.17 | 2019-2025 | Hym/Hyn, Hymovis, Triluron |
| Lilly USA, LLC | $554.46 | 2019-2024 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $520.67 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $392.62 | 2019-2025 | Orencia |
| Genentech USA, INC. | $320.72 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.